A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)
This is a study to determine whether investigational V212 reduces the incidence of herpes zoster (HZ) compared to placebo when administered to recipients of autologous hematopoietic cell transplants (HCT).
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- biological : Matching placebo
- biological : V212
Phase: Phase 3
Ages Eligible For Study:
- Men and women at least 18 years of age - Has prior history of varicella, antibodies to VZV (documented prior to receipt of blood products), or residence in a country with endemic VZV infection for ?30 years or if participant is <30 years old, attended primary or secondary school in a country with endemic VZV infection. - Scheduled to undergo an autologous hematopoietic cell transplant within 60 days of enrollment - Is highly unlikely to conceive during the time period starting 2 weeks prior to enrollment through 6 months from last vaccination dose - Female participants of childbearing potential must have a negative serum or urine pregnancy test.